SCHEMBL7465320

SCHEMBL7465320

[CH2]CN(C)C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49
F13A1 P00488 1/20 0.46
TGM2 P21980 1/20 0.46
TGM1 P22735 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
ABCB1 P08183 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA4 P43681 1/20 0.46
LMNA P02545 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11622571 0.87 ALDH1A1 (0.51) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL7367495 0.86 ALDH1A1 (0.58) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL10107202 0.84 ALDH1A1 (0.56) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL13687204 0.84 CHRNB2 (0.61) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL17688549 0.83 ALDH1A1 (0.55) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL316882 0.83 ALDH1A1 (0.55) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL8016043 0.82 ALDH1A1 (0.58) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL13684203 0.82 ALDH1A1 (0.50) ALDH1A1MAPTHPGDTDP1MAPK1
Benzyl Dimethylcarbamate SCHEMBL20401678 0.82 ALDH1A1 (0.62) ALDH1A1MAPTHPGDTDP1MAPK1
Benzyl Dimethylcarbamate SCHEMBL14031385 0.82 ALDH1A1 (0.62) ALDH1A1MAPTHPGDTDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3050883-B1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES MEIJI SEIKA PHARMA CO LTD (JP) 2020-04-22 EP claimed
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US claimed
CN-105555787-B Process for preparation of diazabicyclooctane derivatives and intermediates therefor 明治制果药业株式会社 2017-08-08 CN claimed
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-15 US claimed
EP-3050883-A1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF Meiji Seika Pharma Co., Ltd. (JP) 2016-08-03 EP claimed
US-6043254-A ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-03-28 US claimed
EP-0825989-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-03-04 EP claimed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 WO claimed
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US disclosed
US-10000492-B2 Process for producing diazabicyclooctane derivative MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US disclosed
CN-107501264-A The preparation method of diazabicyclooctane derivative 明治制果药业株式会社 2017-12-22 CN disclosed
US-20170283415-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-10-05 US disclosed
CN-105555787-B Process for preparation of diazabicyclooctane derivatives and intermediates therefor 明治制果药业株式会社 2017-08-08 CN disclosed
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-15 US disclosed
US-5710162-A ANTITUMOR AGENTS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1998-01-20 US disclosed
EP-0785191-A1 FUSED INDAN DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
US-5639770-A SUPEROXIDE INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-06-17 US disclosed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 WO disclosed
EP-0713870-A1 NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-05-29 EP disclosed
EP-0600092-A1 THIAZOLE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000492-B2 Process for producing diazabicyclooctane derivative OGFOD1, HAAO, CLCN2 ALDH1A1 311/4885MAPT 4797/4885HPGD 260/4885
US-20170283415-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE OGFOD1, HAAO, CLCN2 ALDH1A1 311/4885MAPT 4797/4885HPGD 260/4885
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF CLCN2, ODC1, KCNN4 ALDH1A1 685/4885MAPT 4807/4885HPGD 1726/4885
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 ALDH1A1 685/4885MAPT 4807/4885HPGD 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.